Biostatistics Support
Gain stronger clarity in communication with the methodical biostatistics CRO services needed for drug development today!
The MMS team are all superstars! You have delivered to timelines throughout, and we really appreciate it. Thank you!
Expertise and regulatory insights set MMS apart.
Expert biostatisticians at MMS hold the trust of leading pharmaceutical and biotechnology Sponsors. Our biostatistics team has an incomparable, industry-educated skill set and end-game experience to provide support in:
- Sample size calculations,
- Randomization schedules,
- Statistical analysis plans (SAP),
- Data interpretation,
- Collaborative solution finding on data/analysis related hurdles, and much more.
When Sponsors engage an MMS biostatistician, they are guaranteed clarity in understanding the statistical rationale and excellent communication with all team members, including programmers, data management, data scientists, medical writers, and clinicians.
The success of a clinical trial depends on the strength and knowledge of the biostatistics lead. When supporting Sponsors with statistical analyses and protocol development for global health authority responses and/or publication support, the biostatisticians at MMS are experienced, attentive, methodical, and intuitive.
What Differentiates MMS From Other CROs?
responsive
MMS is more responsive, taking responsibility for the success of every project with consistent staff and proactive solutions that exceed the expectations of a CRO partner.
adaptable
MMS is more adaptable, knowing your satisfaction and top outcomes are dependent on our ability to remain nimble and make smart decisions based on scientifically-sound data.
focused
MMS is more focused, providing data-centric solutions and innovative technology and processes that help accelerate and de-risk the development and approval of your therapy.
Suggested For You
webinar
October 22nd, 2024
Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules
perspectives
September 30th, 2024
Meet the Leaders Driving MMS’s European Growth
perspectives
September 30th, 2024
The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry
perspectives
September 24th, 2024
Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry
perspectives
September 11th, 2024
From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs
webinar
September 26th, 2024
Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance
perspectives
September 4th, 2024
Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders
perspectives
August 27th, 2024
Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs
regulatory intelligence
August 27th, 2024
Recent Guidance on Diversity Action Planning
regulatory intelligence
August 26th, 2024
Oncology Programs at the FDA
regulatory intelligence
August 26th, 2024
Three Key Take Reflections on the Recent Donanemab Approval
perspectives
August 20th, 2024
Clinical Study Protocols: A Comprehensive Guide to Best Practices From A Senior Medical Writer